title: Treatment of ischemic optic neuropathy.
abstract: Ischemic damage of the optic nerve has no proven effective treatment. While ischemia related to vasculitis (arteritic) is treated with systemic corticosteroids, the primary goal is to prevent further damage, either in the affected or fellow eye. Thrombolytic or anticoagulation supplementive therapy may be considerations for the future. In the more common idiopathic (nonarteritic) form (NAION), multiple attempts at therapy, including systemic corticosteroids, anticoagulants and antiplatelet agents, diphenylhydantoin, hyperbaric oxygen, and optic nerve sheath decompression have been unsuccessful. The use of levodopa has been proposed but is unproven. Megadose intravenous corticosteroid therapy has not been studied in a systematic way. Neuroprotective strategies are under intense investigation for optic neuropathies including NAION, and clinical trials in humans are in progress. Optic nerve regeneration studies are ongoing in animals. Prophylaxis in NAION is unproven.
authors.affiliation: Jules Stein Eye Institue, Department of Ophthalmology, University of California, 100 Stein Plaza, Los Angeles, CA 90095-7005, USA. arnolda@ucla.edu
authors.forename: Anthony C
authors.initials: AC
authors.lastname: Arnold
authors.forename: Leonard A
authors.initials: LA
authors.lastname: Levin
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D019299:Decompression, Surgical; D006801:Humans; D006931:Hyperbaric Oxygenation; D018917:Optic Neuropathy, Ischemic / Q000628:therapy*
chemical_list: D000305:Adrenal Cortex Hormones